Table 6.
Prevalence of aging-related phenotypes in relation to FOXO3A3 genotype
| FOXO3A3 Genotype |
||||
|---|---|---|---|---|
| TT | TG | GG | P | |
| CHD prevalence, % | ||||
| Average-lived | 32.3 | 18.3 | 23.1 | 0.010 |
| Long-lived | 7.4 | 7.6 | 7.7 | 0.998 |
| All | 25.7 | 14.0 | 15.4 | 0.002 |
| Stroke prevalence, % | ||||
| Average-lived | 6.7 | 8.5 | 7.7 | 0.813 |
| Long-lived | 4.9 | 1.9 | 3.8 | 0.510 |
| All | 6.3 | 5.8 | 5.8 | 0.974 |
| Cancer prevalence, % | ||||
| Average-lived | 22.4 | 18.3 | 11.5 | 0.326 |
| Long-lived | 17.3 | 12.4 | 7.7 | 0.400 |
| All | 21.1 | 15.9 | 9.6 | 0.075 |
| Diabetes prevalence, % | ||||
| Average-Lived | 60.6 | 62.3 | 50.0 | 0.498 |
| Long-Lived | 57.5 | 64.1 | 50.0 | 0.368 |
| All | 59.8 | 63.0 | 50.0 | 0.212 |
P values based on χ2 test comparing frequency of GG genotype to other genotypes for average lived controls (n = 402), long lived cases (n = 213), and all subjects (n = 615).